Ultragenyx Pharmaceutical (RARE) Other Non Operating Income (2013 - 2025)

Ultragenyx Pharmaceutical (RARE) has 13 years of Other Non Operating Income data on file, last reported at -$934000.0 in Q4 2025.

• On a quarterly basis, Other Non Operating Income rose 79.88% year-over-year to -$934000.0 in Q4 2025; TTM through Dec 2025 was $1.0 million, a 120.0% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 120.0% from the prior year.
• Other Non Operating Income for Q4 2025 stood at -$934000.0, up from -$1.0 million in the prior quarter.
• Over the last five years, Other Non Operating Income for RARE reached as high as $3.1 million in Q3 2024 and fell as low as -$4.6 million in Q4 2024.
• Historically, Other Non Operating Income has averaged -$412650.0 across 5 years, with a median of -$557000.0 in 2021.
• Across the five-year window, Other Non Operating Income slumped 1288.06% in 2022 and surged 666.67% in 2023, its largest moves.
• Year by year, Other Non Operating Income stood at -$410000.0 in 2021, then soared by 143.9% to $180000.0 in 2022, then jumped by 666.67% to $1.4 million in 2023, then sank by 436.45% to -$4.6 million in 2024, then soared by 79.88% to -$934000.0 in 2025.
• Per Business Quant data, the three most recent Other Non Operating Income figures were -$934000.0 in Q4 2025, -$1.0 million in Q3 2025, and $2.1 million in Q2 2025.